ArticleJACC. Advances2026
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with acute myeloid leukemia (AML) treated with hypomethylating agents and venetoclax (HMA-VEN) may be at risk for cardiovascular complications. The incidence, associations, and prognostic implications of these events remain poorly defined.
objectivesThe purpose of this study was to evaluate the incidence, risk factors, and prognostic significance of major adverse cardiovascular events (MACE) in AML patients treated with HMA-VEN and to identify clinical and genetic predictors.
methodsWe conducted a multicenter retrospective cohort study across 6 U.S. health care systems between January 2017 and July 2024. The study included 1,012 adults (mean age 69 ± 12.5 years; 57% male) with newly diagnosed or relapsed/refractory AML treated with HMA-VEN. The primary outcome was MACE, defined as atrial fibrillation, heart failure, left ventricular ejection fraction reduction, stroke/transient ischemic attack, acute coronary syndrome, angina, ventricular tachycardia/fibrillation, myocarditis, or cardiovascular death. The secondary outcome was noncardiac mortality. Variables associated with MACE and mortality were analyzed using Fine-Gray competing risk and Cox proportional hazards models.
resultsMACE occurred in 20% of patients (n = 200), with a median time to first MACE of 120 days and a 12-month cumulative incidence of 17%. Atrial fibrillation (6%), stroke/transient ischemic attack (5%), left ventricular ejection fraction reduction (5%), and heart failure (4%) were most frequent. Diabetes independently predicted MACE (subdistribution HR: 1.4; 95% CI: 1.03-1.89; P = 0.031). In the matched cohort, MACE was associated with increased mortality (73% vs 56%; HR: 1.96; 95% CI: 1.59-2.42; P < 0.001).
conclusionsMACE are frequent and occur early in patients with AML treated with HMA-VEN, particularly in patients with diabetes, and are associated with lower survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.